Lymphodepletion Improves Results for Allogenic CAR T-Cell Therapy in ALL
January 7th 2022Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Watch
Zanubrutinib/Venetoclax Shows Efficacy in High-Risk CLL Subgroup
January 5th 2022Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
EP. 4A: The Role of Trilaciclib in the Management of Chemotherapy-Induced Myelosuppression in SCLC
December 22nd 2021In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.
Watch